Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?

Shares of Moderna (MRNA) witnessed a significant increase of more than 13% on Tuesday, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC. The upgrade is based on the belief that Moderna, a Covid vaccine manufacturer, could potentially introduce five new products to the market by 2026.Challenging 2023 for ModernaThe upgrade comes after a challenging year in 2023 for Moderna, a year in which its sole commercially available product was the Covid vaccine. The company's sto ...